Australia

Australia is one of Gavi’s longest-standing partners in the Asia-Pacific, supporting the Vaccine Alliance since 2006 through direct contributions, the International Finance Facility for Immunisation (IFFIm) and the Gavi COVAX AMC. Australia’s leadership in immunisation, public health and health security, together with its strong domestic immunisation programme, underpins its commitment to equitable access to vaccines and resilient health systems.

Australia has provided more than US$ 1.2 billion to Gavi since 2006, including significant direct contributions and long-term support through IFFIm. Key commitments include US$ 270 million for 2011–2015; an Australian $250 million, 20-year IFFIm commitment in 2011; US$ 234 million for 2016–2020; and Australian $300 million pledged at the Global Vaccine Summit 2020. During Gavi’s 2021–2025 strategic period (Gavi 5.0/5.1), Australia contributed approximately US$ 380 million to Gavi, including its support to the COVAX AMC during the COVID-19 pandemic. At Gavi’s 2025 high-level pledging summit, Australia pledged a further US$ 259 million for Gavi’s 2026–2030 strategic period (Gavi 6.0) through direct contributions and IFFIm, reaffirming its commitment to immunisation, regional health security and resilience across the Indo-Pacific. 

Australia champions health security and immunisation, recognising vaccines as a strategic investment in health, resilience and development. Through Gavi, it supports stronger immunisation systems, expanded vaccine access and greater preparedness for future health threats. Australia is also a global leader in HPV vaccination and cervical cancer elimination, a priority that aligns closely with Gavi’s efforts to increase HPV vaccine coverage; and improve health outcomes for women and girls across the Indo-Pacific, particularly in Pacific Island countries where cervical cancer remains a significant public health challenge.